dr. Avinindita Nura Lestari, one of our Founding Team members, participated in the 34th Annual Scientific Meeting of the Indonesian Heart Association (ASMIHA) 2025, one of Indonesia’s major national cardiology conferences. The team presented a systematic review entitled “Titin-truncating variants as genetic determinants of chemotherapy-induced cardiomyopathy,” exploring the role of genetic variation in susceptibility to cardiotoxicity following cancer treatment. The work was recognised with the Best Moderated Poster – Systematic Review award, highlighting GENEPICA’s contribution to research at the intersection of cardiovascular genomics, precision medicine, and clinical care.